Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
3.12M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
31.2M
-
Shares change
-
-2.78M
-
Total reported value, excl. options
-
$29.4M
-
Value change
-
-$2.63M
-
Put/Call ratio
-
0
-
Number of buys
-
15
-
Number of sells
-
-28
-
Price
-
$0.94
Significant Holders of Passage BIO, Inc. - COMMON STOCK (PASG) as of Q2 2023
65 filings reported holding PASG - Passage BIO, Inc. - COMMON STOCK as of Q2 2023.
Passage BIO, Inc. - COMMON STOCK (PASG) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.2M shares
.
Largest 10 shareholders include ORBIMED ADVISORS LLC (10.1M shares), Versant Venture Management, LLC (4.96M shares), New Leaf Venture Partners, L.L.C. (2.5M shares), Erste Asset Management GmbH (2.16M shares), BML Capital Management, LLC (2.06M shares), VANGUARD GROUP INC (2.02M shares), Frazier Life Sciences Management, L.P. (1.85M shares), Lynx1 Capital Management LP (1.17M shares), BlackRock Inc. (1.06M shares), and RENAISSANCE TECHNOLOGIES LLC (979K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.